Sangamo Therapeutics (SGMOQ) Income from Non-Controlling Interests (2018 - 2021)

Sangamo Therapeutics has reported Income from Non-Controlling Interests for 4 years, with the latest figure at -$5000.0 in Q2 2021.

• On a quarterly basis, Income from Non-Controlling Interests rose 86.11% year-over-year to -$5000.0 in Q2 2021; TTM through Mar 2022 was -$5000.0, a 92.96% increase from a year earlier, with the FY2021 full-year figure at -$11000.0, up 91.27% from the prior year.
• Income from Non-Controlling Interests was -$5000.0 for Q2 2021 at Sangamo Therapeutics, up from -$6000.0 in the prior quarter.
• The five-year high for Income from Non-Controlling Interests was $42000.0 in Q3 2020, with the low at -$555000.0 in Q4 2018.
• Average Income from Non-Controlling Interests over 4 years is -$100272.7, with a median of -$54000.0 recorded in 2019.
• The largest YoY upside for Income from Non-Controlling Interests was 123.46% in 2020 against a maximum downside of 31.48% in 2020.
• Over 4 years, Income from Non-Controlling Interests stood at -$555000.0 in 2018, then soared by 90.27% to -$54000.0 in 2019, then slumped by 31.48% to -$71000.0 in 2020, then jumped by 92.96% to -$5000.0 in 2021.
• The last three Income from Non-Controlling Interests figures came in at -$5000.0 (Q2 2021), -$6000.0 (Q1 2021), and -$71000.0 (Q4 2020), per Business Quant data.